Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir

doi:10.12998/wjcc.v11.i34.8139

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 34

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1876)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

1203

Tables (1-5)

132

Sum=1436

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

292

Sum=370

Dec 6, 2023 (publication date) through Jul 21, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Clin Cases. Dec 6, 2023; 11(34): 8139-8146
Published online Dec 6, 2023. doi: 10.12998/wjcc.v11.i34.8139

Table 4 Rates of alanine aminotransferase normalization, hepatitis B e antigen loss, hepatitis B e antigen seroconversion, and hepatitis B surface antigen loss at week 48

Outcome	ETV group (n = 30)	TAF group (n = 30)	P value
ALT normalization (%)	76.7	80.0	0.72
HBeAg loss (%)	25.0	33.3	0.51
HBeAg seroconversion (%)	8.3	33.3	0.04
HBsAg loss (%)	0.0	0.0	> 0.99

ETV: Entecavir; TAF: Tenofovir alafenamide; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen.

Citation: Yuan GC, Chen AZ, Wang WX, Yi XL, Tu L, Peng F, Qiu ZH. Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir. World J Clin Cases 2023; 11(34): 8139-8146
URL: https://www.wjgnet.com/2307-8960/full/v11/i34/8139.htm
DOI: https://dx.doi.org/10.12998/wjcc.v11.i34.8139